<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01104207</url>
  </required_header>
  <id_info>
    <org_study_id>C7448-I</org_study_id>
    <nct_id>NCT01104207</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation for Tinnitus</brief_title>
  <official_title>Clinical Trial of Transcranial Magnetic Stimulation for Relief of Tinnitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness of repetitive transcranial magnetic
      stimulation (rTMS) for reducing the loudness or severity of chronic tinnitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, subject and clinician/observer blind, placebo-controlled
      parallel-group clinical trial of rTMS involving people who experience chronic tinnitus.
      Eligible subjects are randomly assigned to receive either active rTMS treatment or placebo
      treatment to either the left or right side of the head. Subjects receive 2000 pulses of 1 Hz
      rTMS therapy daily on 10 consecutive work days. Outcomes are measured prior to the start of
      treatment and after the last therapeutic session. Follow-up evaluations are conducted 1, 2,
      4, 13 and 26 weeks after the last treatment session. This design allows us to determine if
      rTMS reduces the severity and loudness of tinnitus, the long-term duration of relief, and
      whether the target for coil placement (left/right side of head) affects active rTMS efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Tinnitus Functional Index (TFI) Score</measure>
    <time_frame>26 weeks post-treatment</time_frame>
    <description>The TFI is a 25-item questionnaire that assesses tinnitus severity. The possible range of scores for the TFI is 0 to 100, with higher scores indicating more severe tinnitus.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half of the study participants will receive 2000 pulses of 1 Hz active rTMS daily on 10 consecutive work days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Half of the study participants will receive 2000 pulses of 1 Hz placebo rTMS daily on 10 consecutive work days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive transcranial magnetic stimulation (rTMS)</intervention_name>
    <description>rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo rTMS</intervention_name>
    <description>placebo rTMS</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of chronic tinnitus.

          -  Able to provide written informed consent.

          -  Subject is naive regarding rTMS.

          -  Age/Gender: minimum 18 years old, with an attempt to sample equal numbers of male and
             female subjects.

          -  Other concurrent treatments: A four-week washout from any other tinnitus treatment or
             management program is required prior to entering this study.

          -  Other medications: No restrictions, provided the dosages have been in place for at
             least 6 months.

          -  Psychological status: Stable enough to complete this study per the opinion of the
             Study Physician.

          -  Hearing function: All degrees of hearing function can be included recognizing that
             profound, bilateral losses will not be able to perform tinnitus evaluations and
             hearing tests, but will be able to rate subjective tinnitus loudness, annoyance and
             impact on life. This is an important subpopulation because of the challenges in
             treating them with acoustic therapy and the need for a medical intervention.

          -  Tinnitus characteristics: All forms of tinnitus etiology will be accepted, providing
             the following criteria are met:

               -  Tinnitus duration: Not less than 1 year. Cases of less than 1 year duration have
                  increased likelihood of resolving spontaneously.

               -  Stability: Constant (not pulsatile, intermittent, varying to a high degree in
                  loudness or changing in location of perception). Fluctuating tinnitus reduces the
                  reliability of test-retest measures for loudness.

               -  Self-rated tinnitus loudness: &gt;= 6 on a visual numerical scale (VNS: 0 labeled
                  &quot;No Tinnitus&quot;, 10 labeled &quot;Very Loud&quot;). This outcome measure will provide a
                  subjective indication of immediate changes in perceived loudness.

               -  Location of tinnitus perception: Unrestricted. Tinnitus may be unilateral,
                  bilateral, or perceived in the head.

        Exclusion Criteria:

          -  Medical conditions: No active neurologic or otologic disease processes that may impact
             tinnitus perception. No auto-immune diseases. No pregnancy or planned pregnancy during
             the study. No women who are lactating or are of child-bearing-age without using
             contraception.

          -  Objective Tinnitus - tinnitus that is audible to other people in addition to the
             patient. This type of tinnitus is rare and is unlikely to respond to rTMS because it
             is not associated with abnormal neural activity in the central auditory system.

          -  History or evidence of significant brain malformation or neoplasm, head injury,
             cerebral vascular events (such as strokes), neurodegenerative disorders affecting the
             brain (such as Parkinson's Disease, ALS, Huntington's Disease or Multiple Sclerosis)
             or prior brain surgery.

          -  Cardiac pace makers, other electronic implants (including cochlear implants),
             intracranial or intraocular metallic particles.

          -  History of seizures or epileptic activity.

          -  Patients who cannot communicate reliably with the investigator or who are not likely
             to cope with the requirements of the trial.

          -  Participation in a clinical trial within the last 30 days before the start of this
             one.

          -  Maximum number of previous clinical trials for tinnitus in which subjects may have
             participated: two.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Folmer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Portland Health Care System, Portland, OR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Portland Health Care System, Portland, OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <results_first_submitted>January 4, 2017</results_first_submitted>
  <results_first_submitted_qc>January 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2017</results_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tinnitus</keyword>
  <keyword>TMS</keyword>
  <keyword>transcranial magnetic stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>For half of the subjects, rTMS will be delivered to one side of the head.
repetitive transcranial magnetic stimulation (rTMS): rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>For half of the subjects, placebo rTMS will be delivered to one side of the head.
placebo rTMS: placebo rTMS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>For half of the subjects, rTMS will be delivered to one side of the head.
repetitive transcranial magnetic stimulation (rTMS): rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>For half of the subjects, placebo rTMS will be delivered to one side of the head.
placebo rTMS: placebo rTMS</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="9.5"/>
                    <measurement group_id="B2" value="62.8" spread="8.3"/>
                    <measurement group_id="B3" value="60.6" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tinnitus Functional Index</title>
          <description>The TFI is a 25-item questionnaire that assesses tinnitus severity. The possible range of scores for the TFI is 0 to 100, with higher scores indicating more severe tinnitus.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.8" spread="19.4"/>
                    <measurement group_id="B2" value="40.6" spread="22.2"/>
                    <measurement group_id="B3" value="42.7" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Tinnitus Functional Index (TFI) Score</title>
        <description>The TFI is a 25-item questionnaire that assesses tinnitus severity. The possible range of scores for the TFI is 0 to 100, with higher scores indicating more severe tinnitus.</description>
        <time_frame>26 weeks post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>For half of the subjects, rTMS will be delivered to one side of the head.
repetitive transcranial magnetic stimulation (rTMS): rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>For half of the subjects, placebo rTMS will be delivered to one side of the head.
placebo rTMS: placebo rTMS</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tinnitus Functional Index (TFI) Score</title>
          <description>The TFI is a 25-item questionnaire that assesses tinnitus severity. The possible range of scores for the TFI is 0 to 100, with higher scores indicating more severe tinnitus.</description>
          <units>units on TFI scale; change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" spread="15.2"/>
                    <measurement group_id="O2" value="-2.9" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>For half of the subjects, rTMS will be delivered to one side of the head.
repetitive transcranial magnetic stimulation (rTMS): rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>For half of the subjects, placebo rTMS will be delivered to one side of the head.
placebo rTMS: placebo rTMS</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert L. Folmer, Ph.D.</name_or_title>
      <organization>VA Portland Medical Center</organization>
      <phone>503-220-8262 ext 51868</phone>
      <email>Robert.Folmer@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

